Accumulating evidences have demonstrated that targeting the gut–liver axis might be a new approach to prevent or treat NAFLD, including the application of antibiotics, pre-/pro-/synbiotics and farnesoid X receptor (FXR) agonists. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.